A somatic mutation of RasGRP3 decreases Na/I symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway

about

A somatic mutation of RasGRP3 decreases Na/I symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway

Item

http://www.wikidata.org/entity/Q57494116

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@en

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@nl

type

Item

label

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@en

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@nl

prefLabel

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@en

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@nl

P1476

A somatic mutation of RasGRP3 ...... ting the Akt signaling pathway

@en

P2093

Jianlu Song

http://www.w3.org/2001/XMLSchema#string

Wangwang Qiu

http://www.w3.org/2001/XMLSchema#string

Xianzhao Deng

http://www.w3.org/2001/XMLSchema#string

Youben Fan

http://www.w3.org/2001/XMLSchema#string

Zhili Yang

http://www.w3.org/2001/XMLSchema#string

Zhongling Qiu

http://www.w3.org/2001/XMLSchema#string

P2860

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells

Molecular pathogenesis and mechanisms of thyroid cancer

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

BRAF mutation in thyroid cancer.

miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.

Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells

Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas

Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

P304

1847-1855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30323976

http://www.w3.org/2001/XMLSchema#string

P932

6176176

http://www.w3.org/2001/XMLSchema#string